Dr. Anthony J. Gerbino, MD

Dr. Gerbino practices at Virginia Mason Medical Center - HOPD in Seattle, Washington.

Dr. Gerbino's NPI, 1457461311, was assigned on August 30, 2006. Dr. Gerbino graduated from David Geffen School of Medicine at UCLA in 1992. Dr. Gerbino holds Washington license MD00032310.

Dr. Gerbino's primary practice is Virginia Mason Medical Center - HOPD, at 1100 9th Ave, Seattle, WA 98101.

Dr. Gerbino's primary practice is Virginia Mason Medical Center - HOPD in Seattle, Washington. Dr. Gerbino is also affiliated with Virginia Mason Medical Center. The medical group on file is Virginia Mason Medical Center. Dmand AI also links Dr. Gerbino to 2 more group practices and clinics, 1 hospice, 1 imaging center and 1 medical group, each named with a free account. Dr. Gerbino's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gerbino practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Gerbino's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Gerbino is board certified in critical care medicine by the American Board of Internal Medicine. Dr. Gerbino is licensed in Washington.

Dmand AI lists asthma, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pleural effusion, pneumonia, pulmonary fibrosis and pulmonary heart disease among the conditions Dr. Gerbino treats.

CMS data shows 1,303 Medicare services from Dr. Gerbino across 15 procedure codes in 2024, for 499 Medicare patients. Medicare paid $83,974 for them.

CMS counts 499 Medicare patients who saw Dr. Gerbino in 2024. The largest group is 75 to 84, with 221 patients. 62% of them have high blood pressure, and 61% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gerbino's median patient age at 73, with 53% women.

In 2024, Dr. Gerbino wrote 2,336 Medicare Part D claims for 406 patients. 51% of them were for generic drugs. CMS names the drug for 2,092 of them, across 44 drugs with 11 or more claims each, at $2,056,325 in total drug cost. In 2023, CMS named 1,992 claims across 42 drugs.

Dr. Gerbino accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gerbino as offering telehealth.

Dmand AI links 21 papers to Dr. Gerbino, published from 2020 to 2024. 2020 was the busiest year, with 2. Dr. Gerbino's most frequent co-authors are James R. Holm, MD, Margot A. Schwartz, MD and Jesselle E. Albert, MD.

CMS Open Payments shows 6 general payments to Dr. Gerbino from 4 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 79% of the total. Actelion Pharmaceuticals US, Inc. paid the most, $139.

Dmand AI lists 12 awards for Dr. Gerbino, most recently CMS Stage 1 EHR in 2013.

Dr. Gerbino graduated from David Geffen School of Medicine at UCLA in 1992.

Dr. Gerbino is in network with 17 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.